ImetelChat

EOM

Commsman, the evil and sadness of cancer has affected us all. Thank you for sharing this touching family story. bp

Ryan, I think you were the one who said Geron was screening on the basis of molecular signature and I took issue since there was no mention on the clinical trials site. Looks like you will tun out to be right for future use!! I hope so. Regards, bp

Worth a read in light of the WIPO post:

https://www.nature.com/articles/leu2013 ... rigin=ppub

For those of you who obsessively check Geron's home page (I do, but mostly out a a sense of obligation to this board) its pretty clear that the careers section hasn't been updated despite the high probability that the positions have been filled several weeks ago and the options that attach issued. S...

https://s24.q4cdn.com/668523011/files/doc_presentations/2020/Geron-Corporate-Presentation-JPM-Jan-2020-01.13.2020-FINAL.pdf A few observation about the new presentation. 1. Emphasis on new class and IP protection to 2033 (they will need it at this rate). 2. New PIII MDS proposals to FDA--this does n...

STA, I agree completely with your thoughts. A combo study would probably be the slowest path, possibly requiring a PII first. I have been intrigued by this statement in the last PR: " (i) whether regulatory authorities permit the further development of imetelstat for relapsed/refractory MF before Ge...

Signet 01, you are quite correct, but the CD was to be based largely on the MF data if I remember correctly. Later Scarlett said Janssen would also take the MDS data into consideration before making a final decision. Regards, bp

Well its been about 14 months since Gernobyl. Since that time (ignoring the stock price) some very good things have happened. We have a first class management and development team, fast track in two indications, money in the bank, optimistic meetings with the FDA and multiple signals that manufactur...

I would submit that that need is not met. Rux is a treatment for symptoms but has not been clearly associated with disease modification. With front line there is potential to change the course of a uniformly fatal disease. I think the potential to help many more patients live longer and better is be...

What to make of the last press release re the EOP2 meeting with the Feds? Here we have this:"Based on feedback from the meeting, over the coming months Geron plans to submit several Phase 3 trial design proposals in relapsed/refractory MF and to have further discussions with the FDA regarding potent...

I don't think its a matter of number of patients but in Agios case a defined molecular target IDH1, something present in <4% of MDS patients. The FDA seems to like targeted molecular end points. bp

rccola, I don't see why the FDA should feel compelled to grant AA without some period of time to evaluate whatever was presented at the meeting. I am not sure that the jury isn't still out. bp

I just deleted another 6000 (!!) bogus registration attempts. I can only hope that there were some legit requests buried in these requests but I truly have no way to know. So if you are sincerely interested in posting here please send me a PM on SA and I will watch for your request and allow activat...

No not that appendix, this one: https://www.nejm.org/doi/suppl/10.1056/NEJMoa1310523/suppl_file/nejmoa1310523_appendix.pdf As part of the 2015 Tefferi article in the NEJM the 4 CR or PR patients were presented in the appendix. It is worth a read. And yes Bill, for unknown reasons Tefferi "damned wit...

Nope, no surprises, no updates, some early work re combo therapy. Waiting for FDA meeting.

I thought it might be fun to compile a list of what might go before the FDA at the end of PII meeting presumptively scheduled for March 2020. I invite board members to add or subtract and to help rank order in terms of importance: 1. The MF study that demonstrates significant MOS improvement. That d...